Results 181 to 190 of about 3,130,322 (229)

Impact of Complete Cytoreduction Leaving No Gross Residual Disease Associated with Radical Cytoreductive Surgical Procedures on Survival in Advanced Ovarian Cancer

Annals of Surgical Oncology, 2012
To analyze the impact of radical cytoreductive surgery-as part of primary tumor debulking-on the amount of residual tumor and survival in patients with advanced ovarian cancer and to evaluate the prognostic significance of no gross residual disease (RD) after surgery.Medical records of 203 patients with International Federation of Gynecology and ...
Suk-Joon, Chang, Robert E, Bristow, Hee-Sug, Ryu   +2 more
openaire   +3 more sources

Clinicopathological prognostic factors and the role of cytoreduction in surgical stage IVb endometrial cancer: A retrospective multi-institutional analysis of 248 patients in Japan

Gynecologic Oncology, 2012
Toru Nakanishi, Toyomi Satoh, Takahiro Kasamatsu   +2 more
exaly   +2 more sources

Surgical cytoreduction of deep-seated high-grade glioma through tubular retractor.

Journal of Neurosurgery, 2022
OBJECTIVE Maximal safe resection is the goal of surgical treatment for high-grade glioma (HGG). Deep-seated hemispheric gliomas present a surgical challenge due to safety concerns and previously were often considered inoperable.
Sabastian Hajtovic, James X. Sun, Jasjit Multani, Linda L. Herrmann, Hannah Britton, Jose Gautreaux, Lea B Tortolero, Gillian L. Harrison, J. Golfinos, T. Shepherd, O. Tanweer, D. Placantonakis   +11 more
semanticscholar   +1 more source

Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer [PDF]

New England Journal of Medicine, 2019
BackgroundSecondary surgical cytoreduction in women with platinum-sensitive, recurrent epithelial ovarian, primary peritoneal, or fallopian-tube ("ovarian") cancer is widely practiced but has not been evaluated in phase 3 investigation.MethodsWe randomly
Robert L Coleman, David E. Cohn, Joan L Walker   +2 more
exaly   +3 more sources

“Surgical Apgar Score” predicts postoperative complications after cytoreduction for advanced ovarian cancer

Gynecologic Oncology, 2010
Janet S Rader, Feng Gao, David G Mutch
exaly   +2 more sources

Splenectomy During Secondary Cytoreduction for Ovarian Cancer Disease Recurrence: Surgical and Survival Data

Annals of Surgical Oncology, 2006
Ovarian cancer disease recurs predominantly in the abdomen, with the spleen usually involved as part of a vast spread of upper-abdominal disease or, less frequently, as an isolated site of disease recurrence.
Ludovico Muzii, Filippo Bellati, Roberto Angioli   +2 more
exaly   +2 more sources

Splenectomy and Surgical Cytoreduction for Ovarian Cancer

Gynecologic Oncology, 2000
Lee-May Chen, R S Leuchter, Leo D Lagasse   +2 more
exaly   +2 more sources

Role for Surgical Cytoreduction in Multimodality Treatments for Cancer

Annals of Surgical Oncology, 2001
Martin McCarter, Yuman Fong
exaly   +2 more sources

Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach

Gynecologic Oncology, 2004
Nadeem R. Abu-Rustum, Dennis Chi
exaly   +2 more sources

Huge pseudomyxoma peritonei: Surgical strategies and procedures to employ to optimize the rate of complete cytoreductive surgery

European Journal of Surgical Oncology (EJSO), 2016
Complete cytoreductive surgery (CCRS) plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is the best-known treatment for pseudomyxoma peritonei (PMP). In 30% of the cases, PMP realize a widespread involvement of the peritoneal cavity. In these extreme situations, we developed, devoted strategies to optimize the feasibility and safety of CCRS.
Benhaim, Léonor, Honoré, Charles, Goéré, Diane, Delhorme, Jean-Baptiste, Elias, Dominique   +4 more
openaire   +3 more sources